NCI-H69AR Cells
USUSD$550.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
一般資訊
| 說明 | NCI-H69AR is a multidrug-resistant derivative of the parental small cell lung carcinoma (SCLC) cell line NCI-H69. It was developed through continuous selection in increasing concentrations of chemotherapeutic agents such as doxorubicin. As a result, NCI-H69AR serves as a key model system for investigating mechanisms of acquired drug resistance in SCLC. This cell line retains many of the morphological and biochemical features of its parental line but exhibits profound resistance to several cytotoxic agents, making it especially relevant for studying efflux-mediated resistance pathways. The primary mechanism of resistance in NCI-H69AR involves overexpression of the multidrug resistance protein P-glycoprotein (P-gp), encoded by the MDR1 gene. P-gp functions as an ATP-dependent efflux pump that reduces intracellular drug accumulation, particularly for anthracyclines, vinca alkaloids, and epipodophyllotoxins. Additionally, NCI-H69AR exhibits altered expression of membrane-associated proteins, including annexin II, which may be associated with changes in calcium signaling and vesicular trafficking-processes implicated in drug resistance and cellular stress response. These phenotypic alterations make NCI-H69AR a valuable model for identifying modulators of drug resistance and for evaluating the efficacy of agents targeting efflux mechanisms or bypassing resistance pathways altogether. NCI-H69AR has also been used in comparative studies with its parental line to delineate changes in gene and protein expression, drug sensitivity profiles, and response to pharmacologic inhibitors. This comparative framework helps clarify the evolution of drug resistance in cancer and contributes to the design of combination therapies aimed at re-sensitizing resistant tumors. The line is typically cultured in RPMI-1640 medium supplemented with fetal bovine serum and maintained under standard atmospheric conditions. Its robustness and well-characterized resistance phenotype have secured its place in preclinical research on drug resistance in lung cancer. |
|---|---|
| 生物體 | Human |
| 組織 | Metastatic |
| 疾病 | Lung small cell carcinoma |
| 轉移部位 | Pleural effusion |
| 同義詞 | NCI-H69 AR, NCI-H69/AR, H69AR, H-69AR |
特徵
| 年齡 | 55 years |
|---|---|
| 性別 | Male |
| 族裔 | Caucasian |
| 形態學 | Epithelial |
| 細胞類型 | Epithelial like |
| 生長特性 | Adherent |
監管數據
| 引用 | NCI-H69AR (Cytion catalog number 305840) |
|---|---|
| 生物安全等級 | 1 |
| NCBI_TaxID | 9606 |
| Cellosaurus 編號 | CVCL_3513 |
生物分子資料
| 致瘤性 | Yes; Yes, in nude mice |
|---|---|
| 突變譜 | Mutation: PIK3CA, Simple, p.Gly106_Arg108del (c.317_325delGGCAACCGT), Heterozygous (from parent cell line).Mutation, RB1, Simple, p.Glu748Ter (c.2242G>T), Homozygous (from parent cell line).Mutation, TP53, Simple, p.Glu171Ter (c.511G>T), Homozygous (from parent cell line). |
處理方式
| 培養基 | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| 營養補充品 | Supplement the medium with 20% FBS |
| 解離試劑 | Accutase |
| 流體更新 | 2 to 3 times per week |
| 冷凍培養基 | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| 細胞解凍與培養 |
|
| 培養環境 | 37°C, 5% CO2, humidified atmosphere. |
| 運送條款 | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| 儲存條件 | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
品質控制與分子分析
| 不孕症 | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
| 轉移部位: | Pleural effusion |
|---|
分析證明書 (CoA)
| 批次編號 | 證書類型 | 日期 | 型號 |
|---|---|---|---|
| 305840-071125 | 分析證明書 | 18. Dec. 2025 | 305840 |
-
Related products
Related products